Issues at Novo Nordisk lead to shortage of fast-acting diabetes drug

There is a current shortage of Novo Nordisk’s fast-acting diabetes drug Novorapid 100 E/ml in Denmark, the Danish Medicines Agency has announced.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA approves Eli Lilly diabetes drug
For subscribers
Novo Nordisk appoints new general manager for Turkiye
For subscribers